Pimavanserin

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 366 publications

Drugs for dementia.

Drugs for dementia.

Journal: The Medical letter on drugs and therapeutics
Published: March 24, 2026

Expert group recommendations on the use of antipsychotic drugs in patients with somatic diseases. Part II: renal failure, liver failure, neurological diseases.

Expert group recommendations on the use of antipsychotic drugs in patients with somatic diseases. Part II: renal failure, liver failure, neurological diseases.

Journal: Psychiatria polska
Published: January 23, 2026

Expert group recommendations on the use of antipsychotic drugs in patients with somatic diseases. Part I: (metabolic syndrome, cardiovascular diseases).

Expert group recommendations on the use of antipsychotic drugs in patients with somatic diseases. Part I: (metabolic syndrome, cardiovascular diseases).

Journal: Psychiatria polska
Published: January 23, 2026

Prefrontal 5-HT 2A receptors directly contribute to tic ontogeny: translational evidence.

Prefrontal 5-HT 2A receptors directly contribute to tic ontogeny: translational evidence.

Journal: bioRxiv : the preprint server for biology
Published: January 09, 2026

Integrative computational pipeline for the in silico prioritization of potential KIF11-targeting drug candidates in glioblastoma.

Integrative computational pipeline for the in silico prioritization of potential KIF11-targeting drug candidates in glioblastoma.

Journal: Journal of molecular graphics & modelling
Published: December 07, 2025

Antipsychotic Medications in Parkinson's Disease Psychosis; A Systematic Review of Double-Blind, Randomised, Placebo-Controlled Trials.

Antipsychotic Medications in Parkinson's Disease Psychosis; A Systematic Review of Double-Blind, Randomised, Placebo-Controlled Trials.

Journal: Healthcare (Basel, Switzerland)
Published: December 06, 2025

Real-world evidence of pimavanserin utilization among patients with Parkinson's disease psychosis: a review of real-world data that augments data from randomized controlled trials.

Real-world evidence of pimavanserin utilization among patients with Parkinson's disease psychosis: a review of real-world data that augments data from randomized controlled trials.

Journal: Journal of comparative effectiveness research
Published: October 27, 2025

Impact of Early Treatment with Pimavanserin on Healthcare Resource Utilization Among Newly Diagnosed Patients with Parkinson's Disease Psychosis: A Pre-Post Medicare Claims Database Analysis.

Impact of Early Treatment with Pimavanserin on Healthcare Resource Utilization Among Newly Diagnosed Patients with Parkinson's Disease Psychosis: A Pre-Post Medicare Claims Database Analysis.

Journal: Journal of health economics and outcomes research
Published: October 17, 2025

Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases.

Visual Hallucinations in Serotonergic Psychedelics and Lewy Body Diseases.

Journal: Schizophrenia bulletin
Published: October 06, 2025

Pragmatic trial design enhances diversity and retention among research participants with Lewy body diseases.

Pragmatic trial design enhances diversity and retention among research participants with Lewy body diseases.

Journal: NPJ dementia
Published: September 19, 2025

Posttraumatic Stress Disorder Psychopharmacology Algorithm Update-2024-2025.

Posttraumatic Stress Disorder Psychopharmacology Algorithm Update-2024-2025.

Journal: Psychiatry and clinical psychopharmacology
Published: August 29, 2025

Management of Parkinson's disease psychosis-a European perspective.

Management of Parkinson's disease psychosis-a European perspective.

Journal: The Lancet regional health. Europe
Published: August 18, 2025
Showing 1-12 of 366

Last Updated: 04/28/2026